TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 156 filers reported holding TRAVERE THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 1.15 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $1,858,406 | +10.3% | 120,990 | +61.6% | 0.05% | +6.5% |
Q1 2023 | $1,684,141 | +545.3% | 74,884 | +607.9% | 0.05% | +411.1% |
Q3 2022 | $261,000 | -41.6% | 10,579 | -42.6% | 0.01% | -55.0% |
Q2 2022 | $447,000 | -65.5% | 18,437 | -63.3% | 0.02% | -67.2% |
Q1 2022 | $1,296,000 | +332.0% | 50,285 | +420.0% | 0.06% | +221.1% |
Q4 2021 | $300,000 | +2.7% | 9,671 | -51.6% | 0.02% | -24.0% |
Q2 2021 | $292,000 | – | 19,990 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Lynx1 Capital Management LP | 411,680 | $10,609,000 | 9.85% |
VR Adviser, LLC | 1,994,997 | $51,411,000 | 8.33% |
Kynam Capital Management, LP | 870,918 | $22,444,000 | 7.28% |
GREAT POINT PARTNERS LLC | 1,010,000 | $26,028,000 | 6.29% |
Deep Track Capital, LP | 3,134,503 | $80,776,000 | 5.18% |
RA Capital Management | 4,922,941 | $126,864,000 | 2.77% |
ARMISTICE CAPITAL, LLC | 4,958,000 | $127,768,000 | 2.47% |
MPM BioImpact LLC | 277,950 | $7,163,000 | 1.92% |
Sofinnova Investments, Inc. | 658,249 | $16,963,000 | 1.29% |
Perceptive Advisors | 1,845,555 | $47,560,000 | 0.95% |